Company intelligence / Profile preview

Luminaries

Seattle, Washington, USA

Ownership: Private
Development stage: Other

Overview

Luminaries was a biotechnology company focused on developing next-generation cell therapies using gamma delta T cells. The company's platform aimed to create "off-the-shelf" CAR-T therapies that could be more effective and safer than traditional alpha-beta T cell treatments. Their research primarily targeted B-cell malignancies and potential applications in autoimmune disorders. Luminaries was founded by industry veterans with experience from Juno Therapeutics and Kite Pharma. In 2021, the company was acquired by GentiBio to bolster their regulatory T cell (Treg) therapy pipeline.

Therapeutic areas: OncologyImmunology
Modalities: Cell therapyCAR-T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Luminaries.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luminaries.

Explore the full profile